Ladenburg initiated coverage of Calidi with a Buy rating and $1 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi Biotherapeutics Welcomes Dr. George Peoples to Board
- Calidi enters collaboration with Siga Technologies to support RTNova development
- Calidi Biotherapeutics Enhances Funding Through Warrant Exercises
- Calidi Biotherapeutics Enhances Executive Compensation Package
- David LaPre Resigns from Calidi Biotherapeutics Board